Global Neoantigen Cancer Vaccine Market - 1-3 USERS:2022

Market Report Coverage :
Start Year : 2024 - Forecast Year : 2031 - Start Value : $35.5 Million in 2024 - Forecast Value : $1,988.5 Million by 2031 - CAGR % : 0.78%
Description :
Market Report Coverage - Neoantigen Cancer VaccineMarket Segmentation• Product Type - Personalized and Off-the-Shelf• Type of Neovaccine - Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine• Therapeutic Specialty - Lung Cancer, Urinary System Cancer, Melanoma, Liver Cancer, Head and Neck Cancer, and Blood and Bone Marrow Cancer• Line of Therapy - First Line, Second Line, and Later LinesRegional Segmentation• North America - U.S. and Canada• Europe - Germany, U.K., France, Italy, and Spain• Asia-Pacific and Middle East - China, Australia, Japan, South Korea, and IsraelMarket Growth Drivers• Increasing Global Prevalence of Cancer• Increase in Adoption of Personalized Medicine to Tailor Patient’s Treatment on an Individual Level• Significant External Funding for Executing Research and Development ExerciseMarket Challenges• Higher Cost of Personalized Cancer Vaccines• Hurdles in Clinical Development and Optimization Process• Uncertain Reimbursement Scenario• Payer Uncertainty and Outcome-Based Pricing• High Capital Requirement Hampering the Expansion of Global ReachMarket Opportunities• Treatment Gaps• Reduced Turnaround Time and Cost• Partnerships and Collaboration between Various Healthcare Stakeholders• Data AnalyticsKey Companies ProfiledModerna Therapeutics, F. Hoffmann-La Roche Ltd, AstraZeneca plc, Agenus, OSE Immunotherapeutics, Advaxis, Medigene, Neon Therapeutics (Acquired by BioNTech SE), Genocea Biosciences, Immunovative Therapies, Gritstone Oncology, Nouscom, NantBioScience, Immunovaccine, BioLineRx, Geneos TherapeuticsKey Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?• What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?• What key development strategies are implemented by the major players in order to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?• How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of: o Product Type (Personalized and Off-the-Shelf), o Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine) o Line of Therapy (First Line, Second Line, and Later Lines) o Region, including North America, Europe, Asia-Pacific and Middle East• Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?• Which companies are anticipated to be highly disruptive in the future and why?• What are the current treatment gaps, and how neovaccines are expected to fill these gaps?• What are the unmet needs in the global neoantigen cancer vaccine market?Market OverviewThe global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient’s treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.Expert Quote on the Neoantigen Cancer Vaccine Market“The real issues with neovaccines are higher cost, turn-around times, and limited efficacy. The cost and time to manufacture have come down in the last four years, and as technology improves, it will come down more.”The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market, and current clinical landscape.The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub segment and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.Pipeline Segmentation• The emerging neoantigen cancer vaccines are segmented based on product type into personalized and off-the-shelf neovaccines.• The emerging neoantigen cancer vaccines are segmented based on disease/application into lung cancer, urinary system cancer, melanoma, liver cancer, head and neck cancer, and blood and bone marrow cancer.• The emerging neoantigen cancer vaccines are segmented based on type of neovaccine into nucleic acid vaccine, peptide vaccine, and dendritic cell vaccine.• The emerging neoantigen cancer vaccines are segmented based on line of therapy into first, second, and later lines therapy.• The emerging neoantigen cancer vaccines are segmented based on development phase into Phase I, II, and III.• The emerging neoantigen cancer vaccines are segmented on the basis of route-of-administration into intradermal, subcutaneous, and intramuscular administrations.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France U.K. SpainAsia-Pacific and Middle East China Japan Australia South Korea Israel
Keywords :
Neoantigen Cancer Vaccine Market, Neoantigen Cancer Vaccine Industry, Neoantigen Cancer Vaccine Report, Neoantigen Cancer Vaccine Market Forecasts, Neoantigen Cancer Vaccine Market Trends, Neoantigen Cancer Vaccine Market Companies, Neoantigen Cancer Vaccine Market Analysis, Neoantigen Cancer Vaccine Industry Analysis, What is Neoantigen Cancer Vaccine, Neoantigen Cancer Vaccine Definition, Neoantigen Cancer Vaccine Market Competitive Landscape, Neoantigen Cancer Vaccine Market Drivers, Neoantigen Cancer Vaccine Market Segments, Neoantigen Cancer Vaccine Market Outlook, Neoantigen Cancer Vaccine Market Opportunity, Neoantigen Cancer Vaccine Market Growth, Neoantigen Cancer Vaccine Market Share, Neoantigen Cancer Vaccine Market Size, Neoantigen Cancer Vaccine Market by Product Type, Neoantigen Cancer Vaccine Market by Pipeline Product, Neoantigen Cancer Vaccine Market by Type of Neovaccine, Neoantigen Cancer Vaccine Market by Line of Therapy, Neoantigen Cancer Vaccine Market by Therapeutic Specialty, Neoantigen Cancer Vaccine Market by Region, Personalized Neoantigen Cancer Vaccine Market, Off-the-Shelf Neoantigen Cancer Vaccine Market, Tedopi Neoantigen Cancer Vaccine Market, Allovax Neoantigen Cancer Vaccine Market, ADXS-Neo Neoantigen Cancer Vaccine Market, GEN-009 Neoantigen Cancer Vaccine Market, RG6180 Neoantigen Cancer Vaccine Market, DC (Dendritic Cells) Neoantigen Cancer Vaccine Market, DNA Neoantigen Cancer Vaccine Market, RNA Neoantigen Cancer Vaccine Market, Peptide Neoantigen Cancer Vaccine Market, Dendritic Cell-Based Neoantigen Cancer Vaccine Market, First Line Neovaccine Regimens Neoantigen Cancer Vaccine Market, Second Line Neovaccine Regimens Neoantigen Cancer Vaccine Market, Later Lines Neovaccine Regimens Neoantigen Cancer Vaccine Market, Melanoma Neoantigen Cancer Vaccine Market, Lung Cancer Neoantigen Cancer Vaccine Market, Urinary System Cancer Neoantigen Cancer Vaccine Market, Liver Cancer Neoantigen Cancer Vaccine Market, Head and Neck Cancer Neoantigen Cancer Vaccine Market, Blood and Bone Marrow Cancer Neoantigen Cancer Vaccine Market, North America Neoantigen Cancer Vaccine Market, Europe Neoantigen Cancer Vaccine Market
Press Release :
According to a new market intelligence report by BIS Research titled, ‘The Global Neoantigen Cancer Vaccine Market’, the market is expected to be valued at $35.5 million in 2024 and is anticipated to grow over $1,988.5 million by 2031. The global neoantigen cancer vaccine market is expected to grow at a CAGR of 77.73% during the forecast period 2024-2031, aided primarily by the expected launch of the first neovaccine in the market.In an era of cancer immunotherapies, the recent introduction of neoantigen cancer vaccines has garnered new hope in the medical community, owing to their ability to induce the body’s natural defenses against abnormal malignancies. Cancers often target antigens present on normal cells in addition to cancerous cells, which further makes the patient’s body vulnerable to attacks in the wrong places by the current mainstays of immunotherapies. However, this undesirable phenomenon provides an opportunity for neoantigen cancer vaccines to step in and fill up the potential treatment gaps by selectively targeting cancer-associated antigens.Neoantigen targeting therapeutics basically works on the strategy of immune system stimulation by the selective expansion of tumor-unique antigens targeted T-cells, which ultimately results in a strong immune response. The advancements in molecular profiling, neoantigen prediction, and next-generation gene sequencing technologies have now enabled neovaccines to couple with checkpoint inhibitors for a more potent and multiplexed treatment response. Several pharmaceutical giants and small-scale biotechnology companies currently have their products pipelined for launches in the market. Vaccines by most of these companies are in the initial stages of clinical development or are in the late (Phase III) stage of clinical development.According to Nitish Singh, Lead Analyst at BIS Research, “North America is expected to be a leading contributor in the global neoantigen cancer vaccine market and is anticipated to contribute approximately 55.50% of the projected global market value in 2024. This region is expected to grow significantly during the forecast period 2024-2031 and will continue to dominate the global market in 2031. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. The Europe region is also expected to contribute a significant share of 35.50% to the global market in 2024.”This report is a meticulous compilation of research on more than 30 players in the market ecosystem. It draws upon insights from in-depth interviews with the key opinion leaders of leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles, including several key players such as Moderna Therapeutics, Medigene, Neon Therapeutics, Advaxis, Agenus, F. Hoffmann-La Roche Ltd, AstraZeneca, Immunovative Therapies, and Nouscom.Key Questions Answered in the Report:• What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?• What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?• What key development strategies are implemented by the major players in order to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?• How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of: o Product Type (Personalized and Off-the-Shelf), o Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine) o Line of Therapy (First Line, Second Line, and Later Lines) o Region, including North America, Europe, Asia-Pacific and Middle East• Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?• Which companies are anticipated to be highly disruptive in the future and why?• What are the current treatment gaps, and how neovaccines are expected to fill these gaps?• What are the unmet needs in the global neoantigen cancer vaccine market?
Companies Mentioned :
Moderna TherapeuticsF. Hoffmann-La Roche LtdAstraZeneca plcAgenusOSE ImmunotherapeuticsAdvaxisMedigeneNeon TherapeuticsGenocea BiosciencesImmunovative TherapiesGritstone OncologyNouscomNantBioScienceImmunovaccineBioLineRxGeneos Therapeutics
Press Release :
According to a new market intelligence report by BIS Research titled, ‘The Global Neoantigen Cancer Vaccine Market’, the market is expected to be valued at $35.5 million in 2024 and is anticipated to grow over $1,988.5 million by 2031. The global neoantigen cancer vaccine market is expected to grow at a CAGR of 77.73% during the forecast period 2024-2031, aided primarily by the expected launch of the first neovaccine in the market.In an era of cancer immunotherapies, the recent introduction of neoantigen cancer vaccines has garnered new hope in the medical community, owing to their ability to induce the body’s natural defenses against abnormal malignancies. Cancers often target antigens present on normal cells in addition to cancerous cells, which further makes the patient’s body vulnerable to attacks in the wrong places by the current mainstays of immunotherapies. However, this undesirable phenomenon provides an opportunity for neoantigen cancer vaccines to step in and fill up the potential treatment gaps by selectively targeting cancer-associated antigens.Neoantigen targeting therapeutics basically works on the strategy of immune system stimulation by the selective expansion of tumor-unique antigens targeted T-cells, which ultimately results in a strong immune response. The advancements in molecular profiling, neoantigen prediction, and next-generation gene sequencing technologies have now enabled neovaccines to couple with checkpoint inhibitors for a more potent and multiplexed treatment response. Several pharmaceutical giants and small-scale biotechnology companies currently have their products pipelined for launches in the market. Vaccines by most of these companies are in the initial stages of clinical development or are in the late (Phase III) stage of clinical development.According to Nitish Singh, Lead Analyst at BIS Research, “North America is expected to be a leading contributor in the global neoantigen cancer vaccine market and is anticipated to contribute approximately 55.50% of the projected global market value in 2024. This region is expected to grow significantly during the forecast period 2024-2031 and will continue to dominate the global market in 2031. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. The Europe region is also expected to contribute a significant share of 35.50% to the global market in 2024.”This report is a meticulous compilation of research on more than 30 players in the market ecosystem. It draws upon insights from in-depth interviews with the key opinion leaders of leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles, including several key players such as Moderna Therapeutics, Medigene, Neon Therapeutics, Advaxis, Agenus, F. Hoffmann-La Roche Ltd, AstraZeneca, Immunovative Therapies, and Nouscom.Key Questions Answered in the Report:• What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?• What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?• What key development strategies are implemented by the major players in order to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?• How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of: o Product Type (Personalized and Off-the-Shelf), o Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine) o Line of Therapy (First Line, Second Line, and Later Lines) o Region, including North America, Europe, Asia-Pacific and Middle East• Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?• Which companies are anticipated to be highly disruptive in the future and why?• What are the current treatment gaps, and how neovaccines are expected to fill these gaps?• What are the unmet needs in the global neoantigen cancer vaccine market?
Headline :
Global Neoantigen Cancer Vaccine Market to Reach $1,988.5 Million by 2031
Table of Contents :
1 Product Definition1.1 Inclusion and Exclusion2 Research Scope2.1 Scope of the Study2.2 Key Questions Answered in the Report3 Research Methodology3.1 Primary Data Sources3.1.1 Secondary Data Sources3.2 Market Estimation Model3.2.1 Factors for Data Prediction and Modelling3.2.2 Assumptions and Limitations4 Neoantigen Cancer Vaccine in Cancer Immunotherapy: Overview4.1 Introduction4.2 Cancer Antigens4.3 Targeting Cancer Neoantigen: A Next Wave of Innovation in Oncology?4.4 Neoantigen Cancer Vaccine Mechanism of Action4.5 Types of Neoantigen Cancer Vaccine (by Product Type)4.5.1 Personalized Cancer Vaccine4.5.2 Off-the-Shelf Neoantigen Cancer Vaccine4.6 Types of Neoantigen Cancer Vaccine Market (by Type of Neovaccine (Biological Platform))4.6.1 Nucleic Acid/DNA/mRNA Vaccine4.6.2 Peptide Vaccine4.6.3 Dendritic Cell–Based Vaccine4.7 Types of Neoantigen Cancer Vaccine (by Type of Delivery)4.7.1 Lipid-Based Delivery Approaches4.7.1.1 Peptide (SLP) Mediate Vaccine Delivery in Conjunction with an Adjuvant4.7.1.2 Sequential Immunization of Viral Prime and RNA Boost4.7.2 Direct Injection of Unformulated mRNA Vaccines Encoding Neoepitopes4.7.3 Other Approaches4.8 Prediction Software for Neoantigens4.8.1 Limitations of Neoantigen Prediction Process4.9 Limitations of Neoantigen Cancer Vaccine4.9.1 Lower Tumor Mutational Burden4.9.2 Neoantigens Maturity4.1 Future Prospects4.10.1 Multi-Epitope Vaccination4.10.2 Combinatorial Regimen with Targeted Therapies4.10.3 Combinatorial Regimen with Conventional Cancer Therapies5 Industry Insights5.1 Overview of Regulatory Pathway for Neoantigen Cancer Vaccine5.1.1 U.S. FDA Guidelines for Biologics License Application (BLA) Submission5.1.2 European Medicine Agency (EMA) Biologics License Application Process5.1.2.1 Centralized Procedure5.1.2.2 Decentralized Procedure5.1.2.3 Mutual-Recognition Procedure5.2 Regulatory Challenges5.3 Successful Regulatory Strategies5.4 Patent Landscape6 Impact of COVID-19 on the Global Neoantigen Cancer Vaccine Market7 Market Dynamics7.1 Overview7.2 Emerging and Current Market Trends7.3 Market Drivers7.3.1 Increasing Global Prevalence of Cancer7.3.2 Increase in Adoption of Personalized Medicine to Tailor Patient’s Treatment on an Individual Level7.3.3 Significant External Funding for Executing Research and Development Exercise7.4 Market Restraints7.4.1 Higher Cost of Personalized Cancer Vaccines7.4.2 Hurdles in Clinical Development and Optimization Process7.4.3 Uncertain Reimbursement Scenario7.4.4 Payer Uncertainty and Outcome-Based Pricing7.4.5 High Capital Requirement Hampering the Expansion of Global Reach7.5 Market Opportunities7.5.1 Treatment Gaps7.5.2 Reduced Turnaround Time and Cost7.5.3 Partnerships and Collaboration between Various Healthcare Stakeholders7.5.4 Data Analytics8 Pipeline Landscape8.1 Emerging Neoantigen Cancer Vaccine8.2 Clinical Trials Heat Map8.3 Pipeline Analysis8.3.1 By Development Phase8.3.2 By Type of Therapy8.3.3 By Product Type8.3.4 By Treatment Strategy8.3.5 By Type of Neovaccine8.3.6 By Delivery Approach8.3.7 By Line of Therapy8.3.8 By Therapeutic Specialty8.3.9 By Route of Administration8.3.10 By Core Product Status8.3.11 By Neoantigen Payload9 Global Neoantigen Cancer Vaccine Market (by Product Type)9.1 Personalized Neoantigen Cancer Vaccine9.2 Off-the-Shelf Neoantigen Cancer Vaccine10 Global Neoantigen Cancer Vaccine Market (by Pipeline Product)10.1 Tedopi10.2 Allovax10.3 DC (Dendritic Cells) Vaccine10.4 ADXS-Neo10.5 GEN-00910.6 RG618011 Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine)11.1 Nucleic Acid (DNA/RNA Vaccine)11.1.1 DNA Vaccine11.1.2 RNA Vaccine11.2 Peptide Vaccines11.3 Dendritic Cell-Based Vaccine12 Global Neoantigen Cancer Vaccine Market (by Line of Therapy)12.1 First Line Neovaccine Regimens12.2 Second Line Neovaccine Regimens12.3 Later Lines Neovaccine Regimens13 Global Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), 2024-203113.1 Melanoma13.2 Lung Cancer13.3 Urinary System Cancer13.4 Liver Cancer13.5 Head and Neck Cancer13.6 Blood and Bone Marrow Cancer14 Global Neoantigen Cancer Vaccine Market (by Region)14.1 Overview14.2 North America14.3 U.S.14.3.1 Market Size and Forecast14.4 Canada14.4.1 Market Size and Forecast14.5 Europe14.5.1 Germany14.5.1.1 Market Size and Forecast14.5.2 France14.5.2.1 Market Size and Forecast14.5.3 U.K.14.5.3.1 Market Size and Forecast14.5.4 Italy14.5.4.1 Market Size and Forecast14.5.5 Spain14.5.5.1 Market Size and Forecast14.6 Asia-Pacific and Middle East14.6.1 Japan14.6.1.1 Market Size and Forecast14.6.2 China14.6.2.1 Market Size and Forecast14.6.3 Australia14.6.3.1 Market Size and Forecast14.6.4 South Korea14.6.4.1 Market Size and Forecast14.6.5 Israel14.6.5.1 Market Size and Forecast15 Competitive Landscape15.1 Overview15.2 Key Developments and Strategies15.2.1 Partnerships and Alliances15.2.2 Business Expansions15.2.3 Merger and Acquisition Activities15.2.4 Product Approvals15.2.5 Financing Activities15.2.6 Funding Activities15.2.7 Regulatory and Legal Activities16 Company Profiles16.1 Moderna Therapeutics16.1.1 Company Overview16.1.2 Role of Moderna Therapeutics in the Global Neoantigen Cancer Vaccine Market16.1.3 Technology and Capabilities16.1.4 Financials16.1.5 Key Insights about Financial Health of the Company16.1.6 SWOT Analysis:16.2 F. Hoffmann-La Roche Ltd16.2.1 Company Overview16.2.2 Role of F. Hoffmann-La Roche Ltd in the Global Neoantigen Cancer Vaccine Market16.2.3 Technology and Capabilities16.2.3.1 Technology Platform16.2.3.2 Manufacturing16.2.4 Financials16.2.5 Key Insights about Financial Health of the Company16.2.6 SWOT Analysis:16.3 AstraZeneca plc16.3.1 Company Overview16.3.2 Role of AstraZeneca plc in the Global Neoantigen Cancer Vaccine Market16.3.3 Financials16.3.4 Key Insights about Financial Health of the Company16.3.5 SWOT Analysis:16.4 Agenus16.4.1 Company Overview16.4.2 Role of Agenus in the Global Neoantigen Cancer Vaccine Market16.4.3 Technology and Capabilities16.4.3.1 Technology Platforms16.4.3.2 Manufacturing16.4.3.3 Adjuvant16.4.4 Financials16.4.5 Key Insights about Financial Health of the Company16.4.6 SWOT Analysis:16.5 OSE Immunotherapeutics16.5.1 Company Overview16.5.2 Role of OSE Immunotherapeutics in the Global Neoantigen Cancer Vaccine Market16.5.3 Technology and Capabilities16.5.3.1 Technology Platforms16.5.3.2 Manufacturing16.5.4 Financials16.5.5 Key Insights about Financial Health of the Company16.5.6 SWOT Analysis:16.6 Advaxis16.6.1 Company Overview16.6.2 Role of Advaxis in the Global Neoantigen Cancer Vaccine Market16.6.3 Technology and Capabilities16.6.3.1 Technology platform16.6.3.2 Manufacturing16.6.4 Financials16.6.5 Key Insights about Financial Health of the Company16.6.6 SWOT Analysis:16.7 Medigene16.7.1 Company Overview16.7.2 Role of Medigene in the Global Neoantigen Cancer Vaccine Market16.7.3 Technology and Capabilities16.7.3.1 Technology Platform16.7.3.2 Manufacturing16.7.4 Financials16.7.5 Key Insights about Financial Health of the Company16.7.6 SWOT Analysis:16.8 Neon Therapeutics (Acquired by BioNTech SE)16.8.1 Company Overview16.8.2 Role of Neon Therapeutics (Acquired by BioNTech SE) in the Global Neoantigen Cancer Vaccine Market16.8.3 Technology and Capabilities16.8.3.1 Technology Platforms16.8.3.2 Manufacturing16.8.4 SWOT Analysis:16.9 Genocea Biosciences16.9.1 Company Overview16.9.2 Role of Genocea Biosciences in the Global Neoantigen Cancer Vaccine Market16.9.3 Technology and Capabilities16.9.3.1 Technology Platform16.9.3.2 Manufacturing Capabilities16.9.4 SWOT Analysis:16.1 Immunovative Therapies16.10.1 Company Overview16.10.2 Role of Immunovative Therapies in the Global Neoantigen Cancer Vaccine Market16.10.3 Technology and Capabilities16.10.3.1 Technology Platform16.10.3.2 Manufacturing16.10.4 SWOT Analysis:16.11 Gritstone Oncology16.11.1 Company Overview16.11.2 Role of Gritstone Oncology in the Global Neoantigen Cancer Vaccine Market16.11.3 Technology and Capabilities16.11.3.1 Technology Platform16.11.3.2 Manufacturing16.11.4 SWOT Analysis:16.12 Nouscom16.12.1 Company Overview16.12.2 Role of Nouscom in the Global Neoantigen Cancer Vaccine Market16.12.3 Technology and Capabilities16.12.3.1 Technology Platform16.12.3.2 Manufacturing16.12.4 SWOT Analysis:16.13 NantBioScience16.13.1 Company Overview16.13.2 Role of NantBioScience in the Global Neoantigen Cancer Vaccine Market16.13.3 SWOT Analysis:16.14 Immunovaccine16.14.1 Company Overview16.14.2 Role of Immunovaccine in the Global Neoantigen Cancer Vaccine Market16.14.3 SWOT Analysis:16.15 BioLineRx16.15.1 Company Overview16.15.2 Role of BioLineRx in the Global Neoantigen Cancer Vaccine Market16.15.3 SWOT Analysis:16.16 Geneos Therapeutics16.16.1 Company Overview16.16.2 Role of Geneos Therapeutics in the Global Neoantigen Cancer Vaccine Market16.16.3 SWOT Analysis:List of Figures Figure 1: Impact Analysis of Market Drivers and Market Restraints on the Global Neoantigen Cancer Vaccine MarketFigure 2: Global Neoantigen Cancer Vaccine Market Size (by Product Type), $Million, 2024 and 2031Figure 3: Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024 and 2031Figure 4: Global Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024 and 2031Figure 5: Global Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024 and 2031Figure 6: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024 and 2031Figure 7: Global Neoantigen Cancer Vaccine Market SegmentationFigure 8: Global Neoantigen Cancer Vaccine Market: Existing Pipeline SegmentationFigure 9: Global Neoantigen Cancer Vaccine Market Research MethodologyFigure 10: Primary Research MethodologyFigure 11: Bottom-Up Approach (Segment-Wise Analysis)Figure 12: Step by Step ApproachFigure 13: Step by Step Process for Neoantigen Vaccine DevelopmentFigure 14: Type of Cancer AntigensFigure 15: Specialized Therapies Segmentation in the U.S.Figure 16: Neoantigen Cancer Vaccine Mechanism of ActionFigure 17: Factors Affecting Neoantigen Prediction ProcessFigure 18: Future Prospects of NeovaccinesFigure 19: U.S. FDA Review TimelineFigure 20: EMA Review TimelineFigure 21: Share of Patents (by Ownership), 2016-2019Figure 22: Number of Deaths Due to Different Cancer Types, Million, 2020Figure 23: Global Cancer Incidence, Million, 2018Figure 24: Neovaccines Funding and Expansion Activities Breakout, January 2016-September 2019Figure 25: Overall Financing Raised by Emerging Neovaccine Companies, $Million, January 2016-September 2019Figure 26: Overview of Reimbursement Policies in EuropeFigure 27: Market OpportunitiesFigure 28: Key Neoantigen Cancer Vaccine in Clinical Development Phase I, II and III, 2021Figure 29: Neoantigen Cancer Vaccine: Clinical Trials Heat MapFigure 30: Neoantigen Cancer Vaccine: Breakdown of Pipeline (by Development Phase), 2021Figure 31: Neoantigen Cancer Vaccine (by Type of Therapy)Figure 32: Neoantigen Cancer Vaccine (by Product Type)Figure 33: Neoantigen Cancer Vaccine (by Treatment Strategy)Figure 34: Neoantigen Cancer Vaccine (by Type of Neovaccine (Biological Platform))Figure 35: Neoantigen Cancer Vaccine (by Delivery Approach)Figure 36: Neoantigen Cancer Vaccine, by Line of TherapyFigure 37: Number of Neoantigen Cancer Vaccine (by Oncology Speciality)Figure 38: Neoantigen Cancer Vaccine (by Route of Administration)Figure 39: Neoantigen Cancer Vaccine (by Core Product Status)Figure 40: Neoantigen Cancer Vaccine (by Neoantigen Payload)Figure 41: Revenue Contribution of Different Segments (by Product Type), $Million, 2024 and 2031Figure 42: Personalized Neoantigen Cancer Vaccine Market (by Product Type), $Million, 2024-2031Figure 43: Off-the-Shelf Neoantigen Cancer Vaccine Market (by Product Type), $Million, 2024-2031Figure 44: Revenue Contribution of Different Segments (by Pipeline), $Million, 2024 and 2031Figure 45: Tedopi-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031Figure 46: Allovax-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031Figure 47: DC (Dendritic Cells) Vaccine-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031Figure 48: ADXS-Neo-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031Figure 49: GEN-009-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031Figure 50: RG6180-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031Figure 51: Revenue Contribution of Different Segments (by Type of Neovaccine), $Million, 2024 and 2031Figure 52: DNA-Based Neoantigen Cancer Vaccine Market (Nucleic Acid, by Type of Neovaccine), $Million, 2024-2031Figure 53: RNA-Based Neoantigen Cancer Vaccine Market (Nucleic Acid, by Type of Neovaccine), $Million, 2024-2031Figure 54: Peptide Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024-2031Figure 55: Dendritic Cell-Based Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024-2031Figure 56: Revenue Contribution of Different Segments (by Line of Therapy), $Million, 2024 and 2031Figure 57: First Line Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031Figure 58: Second Line Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031Figure 59: Later Lines Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031Figure 60: Melanoma Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031Figure 61: Lung Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031Figure 62: Urinary System Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031Figure 63: Liver Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031Figure 64: Head and Neck Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031Figure 65: Blood and Bone Marrow Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031Figure 66: Global Neoantigen Cancer Vaccine Market (by Region)Figure 67: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024 and 2031Figure 68: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024-2031Figure 69: North America: Market DynamicsFigure 70: North America Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 71: North America Neoantigen Cancer Vaccine Revenue Contribution (by Country), $Million, 2024 and 2031Figure 72: Projections of the Older Adult Population in the U.S., Million, 2016-2060Figure 73: U.S. Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 74: Canada Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 75: Europe: Market DynamicsFigure 76: Europe Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 77: Europe Neoantigen Cancer Vaccine Revenue Contribution (by Country), $Million, 2024 and 2031Figure 78: Germany Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 79: France Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 80: U.K. Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 81: Italy Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 82: Spain Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 83: Asia-Pacific: Market DynamicsFigure 84: Asia-Pacific Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 85: Asia-Pacific and Middle East Revenue Contributions of Various Countries, $Million, 2024 and 2031Figure 86: Japan Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 87: China Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 88: Australia Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 89: South Korea Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 90: Israel Neoantigen Cancer Vaccine Market, $Million, 2024-2031Figure 91: Share of Key Developments and Strategies, January 2016-November 2021Figure 92: Partnerships and Alliances (by Company), January 2016-November 2021Figure 93: Business Expansions (by Company), January 2016-November 2021Figure 94: Merger and Acquisition Activities (by Company), January 2016-November 2021Figure 95: Product Approvals (by Company), January 2016-November 2021Figure 96: Financing Activities (by Company), January 2016-November 2021Figure 97: Funding Activities (by Company), January 2016-November 2021Figure 98: Regulatory and Legal Activities (by Company), January 2016-November 2021Figure 99: Moderna Therapeutics: Technology and CapabilitiesFigure 100: Moderna Therapeutics: Therapeutic Focus SegmentationFigure 101: Moderna Therapeutics: Overall Financials/Revenue, $Million, 2018-2020Figure 102: Moderna Therapeutics.: R&D Expenditure, $Million, 2018-2020Figure 103: Moderna Therapeutics: SWOT AnalysisFigure 104: F. Hoffmann-La Roche Ltd: Overall Product PortfolioFigure 105: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2018-2020Figure 106: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Billion, 2018-2020Figure 107: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Billion, 2018-2020Figure 108: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Billion, 2018-2020Figure 109: F. Hoffmann-La Roche Ltd: SWOT AnalysisFigure 110: AstraZeneca plc: Therapeutic Focus SegmentationFigure 111: AstraZeneca plc: Overall Financials/Revenue, $Billion, 2018-2020Figure 112: AstraZeneca plc: Net Revenue (by Region), $Billion, 2018-2020Figure 113: AstraZeneca plc: R&D Expenditure, $Billion, 2018-2020Figure 114: AstraZeneca plc: SWOT AnalysisFigure 115: Agenus: Technology and Capabilities (as Per Type of Product)Figure 116: Agenus: Therapeutic Focus SegmentationFigure 117: Agenus: Overall Financials/Revenue, $Million, 2018-2020Figure 118: Agenus: R&D Expenditure, $Million, 2018-2020Figure 119: Agenus: SWOT AnalysisFigure 120: OSE Immunotherapeutics: Therapeutic Focus SegmentationFigure 121: OSE Immunotherapeutics: Overall Financials/Revenue, $Million, 2018-2020Figure 122: OSE Immunotherapeutics: R&D Expenditure, $Million, 2016-2018Figure 123: OSE Immunotherapeutics: SWOT AnalysisFigure 124: Advaxis: Therapeutic Focus SegmentationFigure 125: Advaxis: Overall Financials/Revenue, $Million, 2018-2020Figure 126: Advaxis: R&D Expenditure, $Million, 2018-2020Figure 127: Advaxis: SWOT AnalysisFigure 128: Medigene: Therapeutic Focus SegmentationFigure 129: Medigene: Overall Financials/Revenue, $Million, 2018-2020Figure 130: Medigene: R&D Expenditure, $Million, 2018-2020Figure 131: Medigene: SWOT AnalysisFigure 132: Neon Therapeutics: Therapeutic Focus Segmentation (Available From FY2019)Figure 133: Neon Therapeutics (Acquired by BioNTech): SWOT AnalysisFigure 134: Genocea Biosciences: Therapeutic Focus SegmentationFigure 135: Genocea Biosciences: SWOT AnalysisFigure 136: Immunovative Therapies: SWOT AnalysisFigure 137: Gritstone Oncology: Therapeutic Focus SegmentationFigure 138: Gritstone Oncology: SWOT AnalysisFigure 139: Nouscom: Therapeutic Focus Segmentation (Available from FY2019)Figure 140: Nouscom: SWOT AnalysisFigure 141: NantBioScience: SWOT AnalysisFigure 142: Immunovaccine: SWOT AnalysisFigure 143: BioLineRx: SWOT AnalysisFigure 144: Geneos Therapeutics: SWOT AnalysisList of Tables Table 1: Implications of Personalized Cancer Vaccines (PCVs)Table 2: Implications of Off-the-Shelf Neoantigen Cancer VaccineTable 3: Implications of DNA and RNA VaccinesTable 4: Implications of Peptide VaccineTable 5: Implications of Dendritic Cell VaccineTable 6: Prediction Software Utilized by Various CompaniesTable 7: Neoantigen Cancer Vaccines Patent Landscape, by 2019Table 8: Neoantigen Cancer Vaccine (by Type of Therapy)Table 9: Neoantigen Cancer Vaccine (by Line of Therapy)Table 10: Neoantigen Cancer Vaccine (by Route of Administration)Table 11: Neoantigen Cancer Vaccine (by Core Product Type (Licensed Products/ Technology Only))Table 12: Neoantigen Cancer Vaccine (by Neoantigen Payload)Table 13: Neoantigen Cancer Vaccine for Melanoma: Pipeline ProductsTable 14: Neoantigen Cancer Vaccine for Lung Cancer: Pipeline ProductsTable 15: Neoantigen Cancer Vaccine for Urinary Cancer: Pipeline ProductsTable 16: Neoantigen Cancer Vaccine for Head and Neck Cancer: Pipeline ProductsTable 17: Neoantigen Cancer Vaccine for Blood and Bone Marrow Cancer: Pipeline Products